3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Interventions
trametinib
3
dabrafenib
3
binimetinib
2
Trastuzumab
2
Paclitaxel
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Doxorubicin
2
Docetaxel
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
sapanisertib
1
romidepsin
1
ripretinib
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
liposomal doxorubicin
1
larotrectinib
1
ipatasertib
1
glutathione pegylated liposomal doxorubicin
1
erdafitinib
1
entinostat
1
diazepinomicin
1
defactinib
1
copanlisib
1
cobimetinib
1
clevudine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioma
×
cabiralizumab
×
Thoracic
×
Clear all
NCT02526017
2022-03-09
FPA008-003
Five Prime Therapeutics, Inc.
Phase 1
Completed
313 enrolled
30 charts